infliximab-dyyb (Zymfentra) vs JNJ-78934804

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Crohn's Disease

Shared mechanism: TNF-alpha · full Crohn's Disease pipeline

infliximab-dyyb (Zymfentra)

Marketed by Celltrion

Approved in Crohn's Diseasemonoclonal antibody
Reliable signal

NCT03945019 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial with 396 participants entering induction and 343 entering the randomized maintenance comparison (231 receiving CT-P13 SC and 112 placebo). Both prespecified primary endpoints—CDAI-based clinical remission and endoscopic response at week 54—were met, with each comparison reported as p<0.0001.

Next expected readout: December 2026 · NCT06064864 (registry estimate)

No aligned efficacy figure on record for this race.

JNJ-78934804

Developed by Johnson & Johnson

Phase 3 in Crohn's DiseaseCo-antibody combination (guselkumab + golimumab, SC)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: June 2028 · NCT07577843 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Crohn's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointinfliximab-dyyb (Zymfentra)JNJ-78934804
Clinical remission (induction)—Not reported—Trial running · NCT07577843
Endoscopic response (induction)—Not reported—Trial running · NCT07577843
Clinical remission (maintenance)—Not reported—Trial running · NCT07577843
Endoscopic response (maintenance)—Not reported—Trial running · NCT07577843

Clinical remission (induction)

infliximab-dyyb (Zymfentra)
—Not reported
JNJ-78934804
—Trial running · NCT07577843

Endoscopic response (induction)

infliximab-dyyb (Zymfentra)
—Not reported
JNJ-78934804
—Trial running · NCT07577843

Clinical remission (maintenance)

infliximab-dyyb (Zymfentra)
—Not reported
JNJ-78934804
—Trial running · NCT07577843

Endoscopic response (maintenance)

infliximab-dyyb (Zymfentra)
—Not reported
JNJ-78934804
—Trial running · NCT07577843
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

infliximab-dyyb (Zymfentra): registry results are on file for Crohn's Disease, but their comparison mappings are not yet available.

JNJ-78934804: no structured comparison results are available for Crohn's Disease.

Ulcerative Colitis

Shared mechanism: TNF-alpha · full Ulcerative Colitis pipeline

infliximab-dyyb (Zymfentra)

Marketed by Celltrion

Approved in Ulcerative Colitismonoclonal antibody
Reliable signal

NCT04205643 · Phase 3 · completed

The trial was randomized, quadruple-blind, and placebo-controlled, with 548 participants enrolled and 438 participants included in the reported maintenance analysis. The hard clinical primary endpoint—clinical remission by the modified Mayo score at week 54—was met, with 127 of 294 participants receiving CT-P13 versus 30 of 144 receiving placebo (p<0.0001).

No aligned efficacy figure on record for this race.

JNJ-78934804

Developed by Johnson & Johnson

Phase 3 in Ulcerative ColitisCo-antibody combination (guselkumab + golimumab, SC)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: August 2028 · NCT07577856 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Ulcerative Colitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointinfliximab-dyyb (Zymfentra)JNJ-78934804
Clinical remission (induction)—Not reported—Trial running · NCT07577856
Clinical remission (maintenance)—Not reported—Trial running · NCT07577856
Clinical response (induction)—Not reported—Trial running · NCT07577856
Endoscopic improvement (induction)—Not reported—Trial running · NCT07577856
Corticosteroid-free remission (maintenance)—Not reported—Trial running · NCT07577856

Clinical remission (induction)

infliximab-dyyb (Zymfentra)
—Not reported
JNJ-78934804
—Trial running · NCT07577856

Clinical remission (maintenance)

infliximab-dyyb (Zymfentra)
—Not reported
JNJ-78934804
—Trial running · NCT07577856

Clinical response (induction)

infliximab-dyyb (Zymfentra)
—Not reported
JNJ-78934804
—Trial running · NCT07577856

Endoscopic improvement (induction)

infliximab-dyyb (Zymfentra)
—Not reported
JNJ-78934804
—Trial running · NCT07577856

Corticosteroid-free remission (maintenance)

infliximab-dyyb (Zymfentra)
—Not reported
JNJ-78934804
—Trial running · NCT07577856
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

infliximab-dyyb (Zymfentra): registry results are on file for Ulcerative Colitis, but their comparison mappings are not yet available.

JNJ-78934804: no structured comparison results are available for Ulcerative Colitis.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: infliximab-dyyb (Zymfentra)'s landscape · JNJ-78934804's landscape